Inflammation Indicators in Saliva from children and adolescents with Spastic Cerebral Palsy

Not Applicable

Recruiting

• Conditions: Cerebral Palsy; M01.060.406; M01.060.057; C10.228.140.140.254; C07.465.714.258.480

• Registration Number: RBR-2yfbnp
• Lead Sponsor: niversidade Cruzeiro do Sul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-25
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Will be included in this study individuals with a medical diagnosis of spastic type CP.

Exclusion Criteria

Will be excluded individuals with progressive or neurodegenerative lesions will be excluded; Individuals with CP who are taking any drug that interferes with salivary secretion such as anticholinergics, neuroleptics or benzodiazepines for at least 72 hours prior to salivary collection; Or have undergone surgical procedures to control the external flow of saliva.
Still, individuals who do not collaborate with the salivary collection have used antibiotics in the last month, present symptoms of fever, flu, body aches or diarrhea, or even an inflammatory condition on the oral mucosa as a cold sore.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The expected outcome is the reduction in the level of inflammatory markers in saliva.<br><br>The method used to verify the expected outcome will be the evaluation of the level of Interleukin 1beta, Interleukin 6, Interleukin 8, Interleukin 10, Tumor Necrosis Factor and Interleukin 12p70 in saliva.<br><br>The parameter to be used to evaluate the occurrence of the outcome will be a reduction of at least 50% in the level of the inflammatory cytokines.<br><br>Clinical evaluations and saliva collection will be performed before and after treatment for gingivitis.

Secondary Outcome Measures

Name	Time	Method
The expected outcome is the reduction of the degree of gingivitis.<br><br>The method used to verify the expected secondary outcome will be the evaluation of the Gingival Index.<br><br>The parameter to be used to evaluate the occurrence of the outcome will be the verification of a reduction of 50% in the measurements before and after periodontal treatment.